Therapeutic Area | MeSH |
---|---|
respiratory tract diseases | D012140 |
immune system diseases | D007154 |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Fasenra | benralizumab | AstraZeneca | N-761070 RX | 2017-11-14 | 2 products |
Brand Name | Status | Last Update |
---|---|---|
fasenra | Biologic Licensing Application | 2021-02-23 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
asthma | EFO_0000270 | D001249 | J45 |
Code | Description |
---|---|
J0517 | Injection, benralizumab, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Asthma | D001249 | EFO_0000270 | J45 | 3 | 6 | 18 | 6 | 21 | 54 |
Eosinophilia | D004802 | HP_0001880 | D72.1 | — | 2 | 1 | 3 | 4 | 10 |
Chronic urticaria | D000080223 | — | L50.8 | — | 1 | — | 1 | — | 2 |
Allergic bronchopulmonary aspergillosis | D001229 | EFO_0007140 | B44.81 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | 3 | 3 | — | — | 7 |
Nasal polyps | D009298 | HP_0100582 | J33 | — | 1 | 1 | — | 2 | 4 |
Gastroenteritis | D005759 | EFO_1001463 | K52.9 | — | 1 | 2 | — | — | 2 |
Bullous pemphigoid | D010391 | EFO_0007187 | L12 | — | — | 1 | — | — | 1 |
Eosinophilic esophagitis | D057765 | EFO_0004232 | K20.0 | — | — | 1 | — | — | 1 |
Hypereosinophilic syndrome | D017681 | EFO_1001467 | D72.11 | — | — | 1 | — | — | 1 |
Churg-strauss syndrome | D015267 | EFO_0007208 | M30.1 | — | — | 1 | — | — | 1 |
Exercise-induced asthma | D001250 | — | J45.990 | — | — | 1 | — | — | 1 |
Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | 1 | 1 | — | — | 1 |
Leukocyte disorders | D007960 | — | D72.9 | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 2 | — | — | — | 2 |
Neoplasms | D009369 | — | C80 | — | 1 | — | — | 1 | 2 |
Hematologic neoplasms | D019337 | — | — | — | 1 | — | — | — | 1 |
Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | — | — | — | 1 |
Immune system diseases | D007154 | — | D89.9 | — | 1 | — | — | — | 1 |
Inborn genetic diseases | D030342 | EFO_0000508 | — | — | 1 | — | — | — | 1 |
Skin diseases | D012871 | — | L00-L99 | — | 1 | — | — | — | 1 |
Dermatitis | D003872 | HP_0011123 | L30.9 | — | 1 | — | — | — | 1 |
Genetic skin diseases | D012873 | — | — | — | 1 | — | — | — | 1 |
Eczematous skin diseases | D017443 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | — | 1 | 1 |
Drug common name | Benralizumab |
INN | benralizumab |
Description | Benralizumab (humanized mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1742991 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB12023 |
UNII ID | 71492GE1FX (ChemIDplus, GSRS) |